US Bancorp’s Keros Therapeutics KROS Stock Holding History

US Bancorp’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$107	Sell	10 -25	-71%	-$278	﹤0.01%	4128
2026 Q1	$386	Sell	35 -499	-93%	-$7.71K	﹤0.01%	4027
2025 Q4	$10.9K	Hold	534	–	–	﹤0.01%	3307
2025 Q3	$8.45K	Sell	534 -9,330	-95%	-$138K	﹤0.01%	3369
2025 Q2	$132K	Buy	9,864 +9,848	+61,550%	+$133K	﹤0.01%	2287
2025 Q1	$163	Sell	16 -174	-92%	-$2.02K	﹤0.01%	4101
2024 Q4	$3.01K	Sell	190 -57	-23%	-$2.96K	﹤0.01%	3768
2024 Q3	$14.3K	Sell	247 -38	-13%	-$1.88K	﹤0.01%	3234
2024 Q2	$13K	Sell	285 -110	-28%	-$5.91K	﹤0.01%	3220
2024 Q1	$26.1K	Buy	395 +48	+14%	+$2.85K	﹤0.01%	2984
2023 Q4	$13.8K	Buy	+347	New	+$10.9K	﹤0.01%	3201
2023 Q3	–	Sell	-55	Closed	-$2.21K	–	4062
2023 Q2	$2.21K	Hold	55	–	–	﹤0.01%	3665
2023 Q1	$2.35K	Hold	55	–	–	﹤0.01%	3720
2022 Q4	$2.64K	Hold	55	–	–	﹤0.01%	3703
2022 Q3	$2K	Buy	55 +14	+34%	+$485	﹤0.01%	3836
2022 Q2	$1K	Hold	41	–	–	﹤0.01%	3967
2022 Q1	$2K	Hold	41	–	–	﹤0.01%	3838
2021 Q4	$2K	Hold	41	–	–	﹤0.01%	3895
2021 Q3	$2K	Buy	+41	New	+$1.46K	﹤0.01%	3890

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

US Bancorp's KROS Position: Q2 2026 in Review

US Bancorp reduced its Keros Therapeutics (KROS) stake by 71% in Q2 2026, selling an estimated $278 and leaving 10 shares worth $107. The position accounts for ﹤0.01% of the portfolio, ranked #4128.

US Bancorp first reported a position in KROS in Q3 2021 and has held it in 19 quarters since. The position peaked at $132K in Q2 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

US Bancorp held 10 shares of Keros Therapeutics worth $107 as of Q2 2026.
US Bancorp sold 25 Keros Therapeutics shares in Q2 2026, an estimated $278.
Keros Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #4128 holding.
US Bancorp first reported a position in Keros Therapeutics in Q3 2021 and has held it in 19 quarters since.
US Bancorp's Keros Therapeutics position peaked at $132K in Q2 2025.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.